38734273|t|Brain-targeted Tet-1 peptide-PLGA nanoparticles for berberine delivery against STZ-induced Alzheimer's disease in a rat model: Alleviation of hippocampal synaptic dysfunction, Tau pathology, and amyloidogenesis.
38734273|a|Alzheimer's disease (AD) is an age-related neurodegenerative disorder that causes severe dementia and memory loss. Surface functionalized poly(lactic-co-glycolic acid) nanoparticles have been reported for better transport through the blood-brain barrier for AD therapy. This study investigated the improved therapeutic potential of berberine-loaded poly(lactic-co-glycolic acid)/Tet-1 peptide nanoparticles (BBR/PLGA-Tet NPs) in a rat model of sporadic AD. BBR was loaded into the PLGA-Tet conjugate. BBR/PLGA-Tet NPs were physicochemically and morphologically characterized. AD was achieved by bilateral intracerebroventricular (ICV) injection of streptozotocin (STZ). Cognitively impaired rats were divided into STZ, STZ + BBR, STZ + BBR/PLGA-Tet NPs, and STZ + PLGA-Tet NPs groups. Cognitive improvement was assessed using the Morris Water Maze. Brain acetylcholinesterase and monoamine oxidase activities, amyloid beta42 (Abeta42), and brain glycemic markers were estimated. Further, hippocampal neuroplasticity (BDNF, pCREB, and pERK/ERK), Tau pathogenesis (pGSK3beta/GSK3beta, Cdk5, and pTau), inflammatory, and apoptotic markers were evaluated. Finally, histopathological changes were monitored. ICV-STZ injection produces AD-like pathologies evidenced by Abeta42 deposition, Tau hyperphosphorylation, impaired insulin signaling and neuroplasticity, and neuroinflammation. BBR and BBR/PLGA-Tet NPs attenuated STZ-induced hippocampal damage, enhanced cognitive performance, and reduced Abeta42, Tau phosphorylation, and proinflammatory responses. BBR/PLGA-Tet NPs restored neuroplasticity, cholinergic, and monoaminergic function, which are critical for cognition and brain function. BBR/PLGA-Tet NPs may have superior therapeutic potential in alleviating sporadic AD than free BBR due to their bioavailability, absorption, and brain uptake.
38734273	29	33	PLGA	Chemical	MESH:D000077182
38734273	52	61	berberine	Chemical	MESH:D001599
38734273	79	82	STZ	Chemical	MESH:D013311
38734273	91	110	Alzheimer's disease	Disease	MESH:D000544
38734273	116	119	rat	Species	10116
38734273	154	174	synaptic dysfunction	Disease	MESH:C536122
38734273	195	210	amyloidogenesis	Disease	
38734273	212	231	Alzheimer's disease	Disease	MESH:D000544
38734273	233	235	AD	Disease	MESH:D000544
38734273	243	281	age-related neurodegenerative disorder	Disease	MESH:D019636
38734273	301	309	dementia	Disease	MESH:D003704
38734273	314	325	memory loss	Disease	MESH:D008569
38734273	350	379	poly(lactic-co-glycolic acid)	Chemical	MESH:D000077182
38734273	470	472	AD	Disease	MESH:D000544
38734273	544	553	berberine	Chemical	MESH:D001599
38734273	561	590	poly(lactic-co-glycolic acid)	Chemical	MESH:D000077182
38734273	624	632	PLGA-Tet	Chemical	-
38734273	643	646	rat	Species	10116
38734273	665	667	AD	Disease	MESH:D000544
38734273	693	701	PLGA-Tet	Chemical	-
38734273	717	725	PLGA-Tet	Chemical	-
38734273	788	790	AD	Disease	MESH:D000544
38734273	860	874	streptozotocin	Chemical	MESH:D013311
38734273	876	879	STZ	Chemical	MESH:D013311
38734273	882	902	Cognitively impaired	Disease	MESH:D003072
38734273	903	907	rats	Species	10116
38734273	926	929	STZ	Chemical	MESH:D013311
38734273	931	934	STZ	Chemical	MESH:D013311
38734273	942	945	STZ	Chemical	MESH:D013311
38734273	952	960	PLGA-Tet	Chemical	-
38734273	970	973	STZ	Chemical	MESH:D013311
38734273	976	984	PLGA-Tet	Chemical	-
38734273	1067	1087	acetylcholinesterase	Gene	83817
38734273	1229	1233	BDNF	Gene	24225
38734273	1251	1254	ERK	Gene	24338
38734273	1285	1293	GSK3beta	Gene	84027
38734273	1295	1299	Cdk5	Gene	140908
38734273	1305	1309	pTau	Gene	29477
38734273	1312	1324	inflammatory	Disease	MESH:D007249
38734273	1419	1422	STZ	Chemical	MESH:D013311
38734273	1442	1444	AD	Disease	MESH:D000544
38734273	1573	1590	neuroinflammation	Disease	MESH:D000090862
38734273	1604	1612	PLGA-Tet	Chemical	-
38734273	1628	1631	STZ	Chemical	MESH:D013311
38734273	1640	1658	hippocampal damage	Disease	MESH:D000092223
38734273	1738	1753	proinflammatory	Disease	
38734273	1769	1777	PLGA-Tet	Chemical	-
38734273	1906	1914	PLGA-Tet	Chemical	-
38734273	1983	1985	AD	Disease	MESH:D000544
38734273	Association	MESH:D001599	MESH:D013311
38734273	Negative_Correlation	MESH:D001599	MESH:D000544
38734273	Positive_Correlation	MESH:D013311	MESH:D000090862
38734273	Association	MESH:D000077182	MESH:D001599
38734273	Negative_Correlation	MESH:D000077182	MESH:D000544
38734273	Negative_Correlation	MESH:D001599	MESH:C536122
38734273	Positive_Correlation	MESH:D013311	MESH:D000092223
38734273	Positive_Correlation	MESH:D013311	MESH:D000544

